Recursion Pharmaceuticals (NASDAQ:RXRX) Hits New 1-Year Low - Here's What Happened

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX - Get Free Report) shares reached a new 52-week low on Tuesday . The company traded as low as $5.84 and last traded at $5.93, with a volume of 1322230 shares traded. The stock had previously closed at $6.10.

Analyst Upgrades and Downgrades

A number of research firms have recently commented on RXRX. Jefferies Financial Group reduced their price objective on shares of Recursion Pharmaceuticals from $8.00 to $6.00 and set a "hold" rating on the stock in a research note on Tuesday, September 3rd. Leerink Partners reduced their price objective on shares of Recursion Pharmaceuticals from $9.00 to $8.00 and set a "market perform" rating on the stock in a research note on Tuesday, September 3rd. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $11.00 price objective on shares of Recursion Pharmaceuticals in a research note on Thursday, November 7th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat.com, the company currently has an average rating of "Hold" and an average price target of $9.25.

Recursion Pharmaceuticals Stock Up 2.8 %

The company has a current ratio of 4.35, a quick ratio of 4.35 and a debt-to-equity ratio of 0.04. The stock's 50-day moving average is $6.66 and its 200-day moving average is $7.55. The company has a market cap of $1.80 billion, a price-to-earnings ratio of -4.10 and a beta of 0.81.

Recursion Pharmaceuticals (NASDAQ:RXRX - Get Free Report) last released its earnings results on Wednesday, November 6th. The company reported ($0.34) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.33) by ($0.01). Recursion Pharmaceuticals had a negative net margin of 579.52% and a negative return on equity of 76.56%. The company had revenue of $26.08 million for the quarter, compared to analyst estimates of $12.62 million. During the same quarter in the previous year, the firm earned ($0.43) EPS. The firm's revenue was up 147.6% on a year-over-year basis. On average, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current fiscal year.

Insider Activity at Recursion Pharmaceuticals

In other Recursion Pharmaceuticals news, CFO Michael Secora sold 15,000 shares of the company's stock in a transaction on Wednesday, November 13th. The shares were sold at an average price of $7.66, for a total transaction of $114,900.00. Following the transaction, the chief financial officer now owns 1,499,631 shares in the company, valued at approximately $11,487,173.46. This represents a 0.99 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, COO Tina Marriott sold 6,000 shares of the company's stock in a transaction on Thursday, August 29th. The stock was sold at an average price of $7.56, for a total transaction of $45,360.00. Following the transaction, the chief operating officer now owns 521,138 shares in the company, valued at approximately $3,939,803.28. The trade was a 1.14 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 171,682 shares of company stock worth $1,133,471 in the last quarter. Company insiders own 15.75% of the company's stock.

Institutional Inflows and Outflows

Several institutional investors have recently bought and sold shares of RXRX. Perceptive Advisors LLC purchased a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at about $5,769,000. Pier 88 Investment Partners LLC raised its holdings in shares of Recursion Pharmaceuticals by 442.1% in the third quarter. Pier 88 Investment Partners LLC now owns 133,910 shares of the company's stock valued at $882,000 after purchasing an additional 109,210 shares during the last quarter. Benjamin F. Edwards & Company Inc. raised its holdings in shares of Recursion Pharmaceuticals by 6,439.6% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 169,900 shares of the company's stock valued at $1,274,000 after purchasing an additional 167,302 shares during the last quarter. Scientech Research LLC purchased a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at about $1,052,000. Finally, Ghisallo Capital Management LLC purchased a new stake in shares of Recursion Pharmaceuticals in the second quarter valued at about $8,250,000. Institutional investors and hedge funds own 89.06% of the company's stock.

About Recursion Pharmaceuticals

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.